These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29317553)

  • 21. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
    Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
    Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Totality of the evidence at work: The first U.S. biosimilar.
    Holzmann J; Balser S; Windisch J
    Expert Opin Biol Ther; 2016; 16(2):137-42. PubMed ID: 26634611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
    Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
    Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies.
    Harbeck N; Wang J; Otto GP; Gattu S; Krendyukov A
    Future Oncol; 2019 Apr; 15(12):1313-1322. PubMed ID: 30834780
    [No Abstract]   [Full Text] [Related]  

  • 27. Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
    Ashariati A; Bintoro UY; Savitri M; Diansyah MN; Amrita PNA; Romadhon PZ; Wijaya AY; Hendrata WM; Looi SS; Mahmudin AA
    Acta Med Indones; 2022 Jul; 54(3):371-378. PubMed ID: 36156473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
    Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
    Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
    J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
    Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
    Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
    Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
    Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
    BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
    Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
    Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.
    Damaj GL; Benbrahim O; Hacini M; Voronina I; Benabed K; Soumoudronga RF; Gasnereau I; Haioun C; Solal-Céligny P
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):362-369.e2. PubMed ID: 28622961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
    Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.